PHAXIAM Therapeutics S.A. (0QSS.L)
EUR 1.76
(1.03%)
EUR 1.76
(1.03%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -5.00 EUR | -7263.77% |
| 2022 | -0.07 EUR | 99.68% |
| 2021 | -20.99 EUR | 43.04% |
| 2020 | -36.85 EUR | -14.12% |
| 2019 | -32.29 EUR | -63.91% |
| 2018 | -19.70 EUR | 27.71% |
| 2017 | -27.25 EUR | -6.95% |
| 2016 | -25.48 EUR | -18.07% |
| 2015 | -21.58 EUR | -43.1% |
| 2014 | -15.08 EUR | 13.33% |
| 2013 | -17.40 EUR | -181.1% |
| 2012 | -6.19 EUR | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.88 EUR | 4.35% |
| 2024 Q2 | -0.88 EUR | 0.0% |
| 2023 Q2 | -2.61 EUR | -40.32% |
| 2023 FY | - EUR | -6704.12% |
| 2023 Q3 | -0.94 EUR | 63.98% |
| 2023 Q4 | -0.92 EUR | 2.13% |
| 2023 Q1 | -1.86 EUR | -875.0% |
| 2022 Q3 | -1.53 EUR | -393.55% |
| 2022 FY | - EUR | 99.68% |
| 2022 Q4 | 0.24 EUR | 115.69% |
| 2022 Q2 | -0.31 EUR | 91.27% |
| 2022 Q1 | -3.55 EUR | 53.9% |
| 2021 Q3 | -5.41 EUR | 52.17% |
| 2021 FY | - EUR | 43.04% |
| 2021 Q4 | -7.70 EUR | -42.33% |
| 2021 Q1 | -5.36 EUR | 71.55% |
| 2021 Q2 | -11.31 EUR | -111.01% |
| 2020 Q4 | -18.84 EUR | -101.5% |
| 2020 FY | - EUR | -14.12% |
| 2020 Q1 | -9.06 EUR | 47.33% |
| 2020 Q2 | -18.01 EUR | -98.79% |
| 2020 Q3 | -9.35 EUR | 48.08% |
| 2019 Q1 | -6.25 EUR | -30.21% |
| 2019 Q2 | -16.33 EUR | -161.28% |
| 2019 FY | - EUR | -63.91% |
| 2019 Q4 | -17.20 EUR | -120.51% |
| 2019 Q3 | -7.80 EUR | 52.24% |
| 2018 Q4 | -4.80 EUR | 20.0% |
| 2018 Q3 | -6.00 EUR | -48.15% |
| 2018 Q2 | -4.05 EUR | 48.08% |
| 2018 Q1 | -7.80 EUR | -9.86% |
| 2018 FY | - EUR | 27.71% |
| 2017 Q4 | -7.10 EUR | -56.39% |
| 2017 Q1 | -6.40 EUR | 10.99% |
| 2017 Q2 | -6.44 EUR | -0.63% |
| 2017 FY | - EUR | -6.95% |
| 2017 Q3 | -4.54 EUR | 29.5% |
| 2016 Q2 | -7.60 EUR | -31.49% |
| 2016 Q4 | -7.19 EUR | 0.0% |
| 2016 Q3 | -7.19 EUR | 5.39% |
| 2016 FY | - EUR | -18.07% |
| 2016 Q1 | -5.78 EUR | 4.3% |
| 2015 Q4 | -6.04 EUR | 0.0% |
| 2015 Q3 | -6.04 EUR | -27.16% |
| 2015 FY | - EUR | -43.1% |
| 2015 Q2 | -4.75 EUR | 0.0% |
| 2015 Q1 | -4.75 EUR | -3.26% |
| 2014 Q4 | -4.60 EUR | 0.0% |
| 2014 Q1 | -2.85 EUR | 23.39% |
| 2014 Q3 | -4.60 EUR | -61.4% |
| 2014 Q2 | -2.85 EUR | 0.0% |
| 2014 FY | - EUR | 13.33% |
| 2013 FY | - EUR | 74.75% |
| 2013 Q2 | -5.25 EUR | 0.0% |
| 2013 Q3 | -3.72 EUR | 29.14% |
| 2013 Q1 | -5.25 EUR | -265.09% |
| 2013 Q4 | -3.72 EUR | 0.0% |
| 2012 Q4 | 3.18 EUR | 0.0% |
| 2012 FY | - EUR | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Boiron SA | 2.06 EUR | 342.718% |
| Laboratorios Farmaceuticos Rovi, S.A. | 3.20 EUR | 256.25% |
| Vetoquinol SA | 4.70 EUR | 206.383% |
| Valneva SE | -0.73 EUR | -584.932% |
| AB Science S.A. | -0.20 EUR | -2400.0% |
| Nanobiotix S.A. | -1.08 EUR | -362.963% |
| Vivoryon Therapeutics N.V. | -1.12 EUR | -346.429% |
| BioSenic S.A. | -0.21 EUR | -2280.952% |
| ABIVAX Société Anonyme | -3.43 EUR | -45.773% |
| Formycon AG | 4.76 EUR | 205.042% |